Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.6B |
| 2 |
Broadcom
AVGO
|
+$1.11B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$882M |
| 4 |
JPMorgan Chase
JPM
|
+$628M |
| 5 |
Tesla
TSLA
|
+$594M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$1.54B |
| 2 |
Visa
V
|
+$1.39B |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.13B |
| 4 |
Amazon
AMZN
|
+$771M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$575M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 45.6% |
| 2 | Technology | 19.83% |
| 3 | Financials | 7.37% |
| 4 | Consumer Discretionary | 6.6% |
| 5 | Communication Services | 5.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4851
Actinium Pharmaceuticals
ATNM
$36.8M
| $3.51K | ﹤0.01% |
2,508
-37,363
| -94% | -$55.9K |
2023 Q1
9 quarters
|
|
|
APLT
4852
DELISTED
Applied Therapeutics
APLT
| $3.45K | ﹤0.01% |
11,103
-117,981
| -91% | -$45.6K |
2024 Q1
5 quarters
|
|
4853
iShares Russell 1000 ETF
IWB
$49.1B
| $3.4K | ﹤0.01% |
10
| – | – |
2025 Q1
1 quarter
|
|
4854
BlackRock Core Bond Trust
BHK
$590M
| $3.36K | ﹤0.01% |
+346
| New | +$3.5K |
2025 Q2
0 quarters
|
|
4855
Ostin Technology Group
OST
| $3.34K | ﹤0.01% |
+844
| New | +$85.3K |
2025 Q2
0 quarters
|
|
4856
Brookfield Infrastructure Partners
BIP
$16.8B
| $3.32K | ﹤0.01% |
99
-8
| -7% | -$251 |
2013 Q4
46 quarters
|
|
|
DM
4857
DELISTED
Desktop Metal, Inc.
DM
| $3.3K | ﹤0.01% |
666
-609
| -48% | -$3.02K |
2022 Q1
13 quarters
|
|
|
GAU
4858
Galiano Gold
GAU
$521M
| $3.17K | ﹤0.01% |
2,500
| – | – |
2022 Q1
13 quarters
|
|
|
IGMS
4859
DELISTED
IGM Biosciences
IGMS
| $3.14K | ﹤0.01% |
2,800
-16,378
| -85% | -$20K |
2022 Q1
13 quarters
|
|
|
LPSN
4860
DELISTED
LivePerson
LPSN
| $3.08K | ﹤0.01% |
203
+115
| +131% | +$1.36K |
2013 Q2
48 quarters
|
|
4861
Nokia
NOK
$59.3B
| $2.94K | ﹤0.01% |
568
-99,432
| -99% | -$512K |
2013 Q2
48 quarters
|
|
|
MRSN
4862
DELISTED
Mersana Therapeutics
MRSN
| $2.89K | ﹤0.01% |
391
-4,478
| -92% | -$39.3K |
2017 Q3
31 quarters
|
|
|
ARTV
4863
Artiva Biotherapeutics
ARTV
$334M
| $2.88K | ﹤0.01% |
1,906
-20,847
| -92% | -$43.8K |
2024 Q3
3 quarters
|
|
4864
PUT
Alkermes
ALKS
$7B
| $2.86K | ﹤0.01% |
+100
| New | +$2.98K |
2025 Q2
0 quarters
|
|
4865
Quest Resource Holding
QRHC
$28.9M
| $2.83K | ﹤0.01% |
1,403
-17,842
| -93% | -$41K |
2024 Q2
4 quarters
|
|
|
BMGL
4866
Basel Medical
BMGL
$5.19M
| $2.78K | ﹤0.01% |
+130
| New | +$5.72K |
2025 Q2
0 quarters
|
|
|
EMO
4867
ClearBridge Energy Midstream Opportunity Fund
EMO
$1,000M
| $2.73K | ﹤0.01% |
57
+25
| +78% | +$1.14K |
2025 Q1
1 quarter
|
|
|
PETWW
4868
DELISTED
Wag! Group Co Warrant
PETWW
| $2.73K | ﹤0.01% |
170,301
| – | – |
2022 Q1
13 quarters
|
|
4869
Westlake Chemical Partners
WLKP
$750M
| $2.69K | ﹤0.01% |
+122
| New | +$2.76K |
2025 Q2
0 quarters
|
|
4870
iShares Emerging Markets Dividend ETF
DVYE
$1.19B
| $2.66K | ﹤0.01% |
93
| – | – |
2017 Q4
30 quarters
|
|
4871
CervoMed
CRVO
$45.7M
| $2.62K | ﹤0.01% |
417
-5,464
| -93% | -$46.6K |
2024 Q2
4 quarters
|
|
4872
iShares MSCI Europe Financials ETF
EUFN
$3.87B
| $2.5K | ﹤0.01% |
+79
| New | +$2.39K |
2025 Q2
0 quarters
|
|
4873
State Street SPDR Nuveen ICE High Yield Municipal Bond ETF
HYMB
$3.5B
| $2.48K | ﹤0.01% |
+100
| New | +$2.46K |
2025 Q2
0 quarters
|
|
|
FARM
4874
DELISTED
Farmer Brothers
FARM
| $2.45K | ﹤0.01% |
1,786
| – | – |
2023 Q2
8 quarters
|
|
4875
Tilly's
TLYS
$140M
| $2.44K | ﹤0.01% |
1,772
-14,635
| -89% | -$20.1K |
2016 Q3
35 quarters
|
|
Similar funds
Barclays's Q2 2025 Portfolio in Review
As of Q2 2025, Barclays held 5,681 positions worth $436B, up 24% from $353B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Barclays's Q2 2025 filing shows 461 new, 2,914 increased, 1,345 reduced and 463 closed positions. Its largest new stake was iShares MBS ETF: 4,310,047 shares worth $405M. The largest sale was Honeywell, an estimated $1.54B.
By sector, the portfolio is most concentrated in Miscellaneous at 46% of assets, up from 41% a quarter earlier, followed by Technology and Financials.
- Barclays's largest Q2 2025 buy was iShares MBS ETF: 4,310,047 shares worth $405M.
- Barclays added most to NVIDIA in Q2 2025, an estimated $1.6B increase.
- Barclays's biggest Q2 2025 reduction was Honeywell, cutting an estimated $1.54B.
- Barclays fully exited Berry Global Group, Inc. in Q2 2025, selling an estimated $173M.
- Barclays's ten largest holdings make up 43% of its $436B portfolio in Q2 2025.
- Barclays opened 461 new positions and closed 463 in Q2 2025.
- Barclays's portfolio value rose 24% quarter-over-quarter to $436B.
Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.